The Pharmacokinetics (PK) of ADC therapeutics typically show a discrepancy between the PK of total antibody and that of conjugated antibody, carrying one or more payload molecules. This discrepancy is often attributed to deconjugation, however recent evidence suggests that the underlying mechanisms may be more complex.
In this webinar, we will present how quantitative systems pharmacology (QSP) modeling approaches provide biological insights into the impact of drug-to-antibody ratio and the resulting changes in molecular properties on overall PK and relative payload disposition as observed in preclinical and clinical studies.
For whom the webinar will be beneficial the most:
Scientists at pharmaceutical companies who are interested in how computational models can be used to design novel ADCs and to optimize the discovery and development of existing ADCs
